“Afrigen Biologics has earned Good Manufacturing Practice (GMP) certification from the South African Health Products Regulatory Authority (SAHPRA), validating Africa’s first fully integrated mRNA manufacturing facility in Cape Town. This achievement strengthens Africa’s health sovereignty by enabling local vaccine production for clinical trials and reducing reliance on imports.”
South Africa has reached a historic milestone in biotechnology with Afrigen Biologics securing GMP certification for its Cape Town-based mRNA manufacturing facility. This achievement is not only a national triumph but also a continental breakthrough, symbolizing Africa’s growing capacity to produce advanced vaccines and biologics. GMP certification validates compliance with global safety and quality standards, enabling Afrigen to manufacture investigational biological products for Phase I and II clinical trials.
Why GMP Certification Matters
- Global Standards Compliance: GMP certification ensures adherence to internationally recognized safety and quality benchmarks.
- Clinical Trial Readiness: Afrigen can now manufacture investigational biological products for clinical trials, a critical step toward vaccine innovation.
- Health Sovereignty: By reducing reliance on imports, South Africa strengthens its ability to respond to pandemics and supply vaccines locally.
Lessons from COVID-19
The COVID-19 pandemic exposed Africa’s vulnerability in vaccine access. Wealthy nations secured doses early, while African countries faced delays and shortages. Afrigen’s facility directly addresses this inequity, ensuring that future pandemics do not leave Africa dependent on external suppliers.
Afrigen’s Journey
- 2022–2023: Conceptualization of the mRNA Technology Transfer Programme, co-led by the World Health Organization (WHO) and the Medicines Patent Pool (MPP).
- 2024–2025: Infrastructure development, recruitment of scientists, and establishment of pilot production lines.
- 2026: GMP certification achieved, marking readiness for clinical trial material production.
Strategic Importance
Afrigen’s facility is more than a national achievement—it is a continental asset.
- Pandemic Preparedness: Rapid response capability for emerging infectious diseases.
- Regional Manufacturing Hub: A platform for vaccine production across Africa.
- Innovation Ecosystem: Collaboration between academia, government, and industry to advance biotechnology.
Voices of Leadership
Prof. Petro Terblanche, CEO of Afrigen, emphasized: “This certification is a tribute to the extraordinary commitment of our team. It represents a new era for Africa’s biotechnology sector.”
Economic and Social Impact
- Job Creation: The facility is expected to generate hundreds of skilled jobs in biotechnology and pharmaceutical manufacturing.
- Capacity Building: Training programs will equip African scientists with cutting-edge skills in mRNA technology.
- Regional Collaboration: Afrigen’s hub will foster partnerships with neighboring countries, strengthening Africa’s collective health resilience.
Challenges Ahead
Despite the achievement, challenges remain:
- Scaling Production: Moving from pilot-scale to full commercial production will require significant investment.
- Regulatory Pathways: Ensuring smooth approval processes across African nations.
- Global Competition: Competing with established pharmaceutical giants in Europe, the U.S., and Asia.
Future Outlook
Afrigen’s GMP certification marks the beginning of a transformative journey. By 2030, the facility aims to produce not only vaccines but also therapeutic biologics, positioning South Africa as a biotechnology powerhouse.
